KOSPIHolding Companies001630

Chongkundang Holdings

₩35,500▲ 0.42%2026-11-18 close
Market Cap
₩177.9B
Turnover
₩56,993,100
Volume
1.6K
Shares out.
5M
PER
4.4×
PBR
0.3×
EPS
₩8,042
Dividend Yield
3.95%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,400 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating Profit Recovers, but Q3 2026 Swings to Net Loss

Chongkundang Holdings is a pure holding company whose operating profit rose to KRW 58.3 billion in 2025, but in Q3 2026 operating profit shrank and the company posted a net loss attributable to controlling shareholders.

  1. 1

    Operating profit reached KRW 58.3 billion in 2025, up 64.2% year on year, and the operating margin climbed from -3.6% in 2022 to 6.1% in 2025.

  2. 2

    Q3 2026 operating profit was KRW 3.57 billion, down 80.3% from a year earlier, and the net loss attributable to controlling shareholders was KRW 1.99 billion.

  3. 3

    Operating profit peaked in Q1 2026 and then declined for two consecutive quarters, in Q2 and Q3.

  4. 4

    Net income attributable to controlling shareholders and net income including non-controlling interests are different figures. In 2025 the former was KRW 40.4 billion and the latter was KRW 54.3 billion.

  5. 5

    The debt-to-equity ratio rose from 72.4% in 2022 to 78.4% in 2025, and total liabilities at the end of 2025 stood at KRW 715.7 billion.

02

Business structure

Chongkundang Holdings was established in November 2013 through a spin-off and operates as a pure holding company.

According to the 2025 business report, nine companies meet the affiliate requirements under the Fair Trade Act, including Chong Kun Dang Pharmaceutical, the API subsidiaries, CKD Bio, a health functional food subsidiary, and a real estate subsidiary.

The holding company's own revenue consists of dividend income and other items, and it accounts for only 2.7% of total revenue. Most consolidated revenue comes from the subsidiaries. In the business report, the product sales ratio of the health functional food subsidiary is 43.1%, the largest single item.

On the pharmaceutical side, Chong Kun Dang Pharmaceutical sells its own products, including a hypertension drug and an osteoarthritis drug, and it is co-selling an obesity treatment under an agreement with Novo Nordisk Pharma Korea.

The API subsidiaries focus on raw pharmaceutical ingredients, and CKD Bio has probiotics and a microbiome-dedicated CDMO facility. One API subsidiary is reported to be developing ADC anticancer conjugation technology to prepare for global ADC CDMO entry.

CKD Bio has filed for Chinese marketing approval of a self-developed botulinum toxin product. The revenue structure rests on two pillars, health functional foods and pharmaceuticals, and API results depend on demand from finished-drug makers.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩234.2B₩18.1B7.7%
2025Q4₩236B₩11.8B5.0%
2026Q1₩240.3B₩19.3B8.0%
2026Q2₩251.2B₩6.6B2.6%
2026Q3₩238.4B₩3.6B1.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩909B-₩32.9B₩1.1B−3.6%0.2%72.4%
2023₩879.8B₩17B₩47B1.9%8.4%76.8%
2024₩957.8B₩35.5B₩33.6B3.7%5.7%76.0%
2025₩959B₩58.3B₩40.4B6.1%6.3%78.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue went from KRW 909 billion in 2022 to KRW 879.8 billion in 2023, down 3.2% year on year, then rose to KRW 957.8 billion in 2024, up 8.9%, and KRW 959 billion in 2025, up 0.1%.

Revenue has grown for two consecutive years from the 2023 low through 2025, and 2025 is the largest year in the 2022 to 2025 period. Operating profit moved from an operating loss of KRW 32.9 billion in 2022 to operating profit of KRW 17 billion in 2023, which marked a turn to profitability.

It then rose to KRW 35.5 billion in 2024, up 108.7%, and KRW 58.3 billion in 2025, up 64.2%. The operating margin went from -3.6% in 2022 to 1.9% in 2023, 3.7% in 2024, and 6.1% in 2025.

Net income attributable to controlling shareholders was KRW 1.07 billion in 2022, KRW 47 billion in 2023, up 4,275.0%, KRW 33.6 billion in 2024, down 28.5%, and KRW 40.4 billion in 2025, up 20.3%.

Net income including non-controlling interests moved from a net loss of KRW 22.7 billion in 2022 to net income of KRW 40.6 billion in 2023, KRW 40.3 billion in 2024, and KRW 54.3 billion in 2025.

In 2023 the figure attributable to controlling shareholders exceeded total net income, which means non-controlling interests recorded a loss that year.

In 2024 operating profit rose while net income attributable to controlling shareholders fell, so non-operating items and income tax are worth checking in the next business report.

On a quarterly basis, revenue was KRW 234.2 billion in Q3 2025, KRW 236 billion in Q4 2025, KRW 240.3 billion in Q1 2026, KRW 251.2 billion in Q2 2026, and KRW 238.4 billion in Q3 2026, which was down 5.1% from the prior quarter and up 1.8% from a year earlier.

Operating profit went from KRW 18.1 billion in Q3 2025 to KRW 11.8 billion in Q4 2025 and KRW 19.3 billion in Q1 2026, then fell to KRW 6.64 billion in Q2 2026 and KRW 3.57 billion in Q3 2026, down 80.3% from a year earlier.

The Q3 2026 net loss attributable to controlling shareholders of KRW 1.99 billion marks a swing from profit a year earlier. The sum of net income attributable to controlling shareholders over the last four quarters is KRW 38.3 billion.

05

Industry analysis

Because a holding company's earnings track its subsidiaries directly, the industry backdrop for this company depends on the pharmaceutical and health functional food markets.

The business report says Chong Kun Dang Pharmaceutical's revenue is affected by government drug pricing policy, and it cites price re-evaluations, the tiered drug pricing system, and the co-bioequivalence 1+3 system as major regulatory variables.

In health functional foods, the health food subsidiary generates revenue mainly through strategic brands such as probiotics and omega-3, and it is sensitive to consumer demand and distribution channel changes.

The API business produces antibiotic and immunosuppressant raw materials and is affected by the demand and cost conditions of finished-drug manufacturers.

Chong Kun Dang Pharmaceutical reported cumulative R&D spending of KRW 161 billion for the first three quarters of 2026, equal to 11.84% of revenue, higher than the 10.98% ratio for full-year 2025. Its operating cash flow also turned from a net outflow a year earlier to a net inflow in the same period.

Compared with Hanmi Science and other listed holding companies in the same sector, this company has many subsidiaries spread across pharmaceuticals, APIs, health functional foods, and real estate.

Its competitive strengths lie in health food brands and raw material production capacity, while medium-term growth depends on clinical results from its new drug pipeline.

06

Outlook

The subsidiary Chong Kun Dang Pharmaceutical announced preliminary standalone revenue of KRW 430.7 billion and operating profit of KRW 23.7 billion for Q3 2026 in a filing with the Financial Supervisory Service on October 30, 2026.

In the same preliminary filing, cumulative revenue for the first three quarters was KRW 1.3538 trillion, up 7.8% year on year, and cumulative operating profit was KRW 61.2 billion, up 10.2%.

Cumulative net income fell 3.6% to KRW 51.6 billion, and the company attributed the decline to foreign currency translation losses from exchange rate moves and higher interest expense.

Because these are standalone preliminary figures of a subsidiary, they are based on a different scope from the holding company's consolidated results and should be read as preliminary until the periodic reports are filed.

The company said that sales growth of newly introduced products, including an obesity treatment and an eye injection, drove the subsidiary's revenue. An Asia Today report said that medium-term profitability improvement depends on the results of new drug development.

At the holding level, CKD Bio's application for Chinese marketing approval of a botulinum toxin product and its microbiome drug pipeline for Alzheimer's disease and MASH are items to watch. The API subsidiary's preparation for ADC CDMO entry is also a marker for whether the raw material business expands.

Fourth-quarter 2026 results have not yet appeared in a periodic report, and the 2026 business report will be the first place where full-year operating profit and the fourth-quarter trend are confirmed.

Because the Q3 2026 operating margin fell from the prior quarter, the next periodic report will show how far the margin recovers.

07

Valuation

PER
4.4×
PBR
0.3×
ROE
6.0%
EPS
₩8,042
BPS
₩137,253
Dividend per share
₩1,400

A holding company's share price is linked both to the value of its subsidiary stakes and to the trend in its own earnings. The price-to-book ratio currently sits well below 1 times, which means the share price is low relative to book net asset value.

Market capitalization is far below the book value of equity attributable to controlling shareholders, so asset value weighs more heavily than the holding company's own earnings in interpreting the share price.

Net income attributable to controlling shareholders over the last four quarters totals KRW 38.3 billion, and after the Q3 2026 swing to a net loss, the earnings base has become much more volatile over a short span.

Dividend capacity depends on the holding company's net income and the dividend income it receives from subsidiaries, so quarterly earnings swings directly affect the reading of dividend capacity.

The multi-year trend shows a clear direction, as the company moved from an operating loss and a net loss in 2022 to profitable results in 2025. In contrast, quarterly earnings have turned into losses since Q3 2026, which narrows the earnings base used in multiple-based readings in a short period.

How this company's valuation reads depends on whether the subsidiary's earnings recovery and the recovery of the holding company's own earnings move in the same direction.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Recovery in operating profit

Operating profit moved from an operating loss of KRW 32.9 billion in 2022 to a turn to profitability in 2023, then rose to KRW 58.3 billion in 2025. The operating margin climbed from -3.6% in 2022 to 6.1% in 2025.

Operating cash flow also improved from -KRW 46.5 billion in 2022 to KRW 76 billion in 2025, which supports the multi-year recovery.

Low share price relative to asset value

Total equity at the end of 2025 was KRW 913.1 billion, of which equity attributable to controlling shareholders was KRW 637 billion. The price-to-book ratio sits well below 1 times, so the share price is low relative to book net assets.

Because the company is a holding company with subsidiary stakes, asset value serves as a reference point for reading the share price.

Subsidiary cash generation and new products

The subsidiary Chong Kun Dang Pharmaceutical reported that cumulative operating cash flow for the first three quarters of 2026 turned to a net inflow of KRW 112.1 billion from a net outflow a year earlier.

The company said newly introduced products, including an obesity treatment and an eye injection, contributed to revenue growth. Interpretations hold that improved cash generation at subsidiaries also expands room for R&D investment. These are subsidiary-level figures and should be read apart from the holding company's consolidated results.

09

Bear factors

Sharp Q3 profit drop and swing to net loss

Q3 2026 operating profit was KRW 3.57 billion, down 80.3% from a year earlier and down 46.2% from the prior quarter. The net loss attributable to controlling shareholders of KRW 1.99 billion marks a swing from profit a year earlier.

Operating profit has declined for two consecutive quarters since peaking in Q1 2026, which is the main bearish factor. This trend makes it harder to confirm that the annual earnings recovery is continuing.

Rising debt and financial burden

The debt-to-equity ratio rose from 72.4% in 2022 to 76.8% in 2023, 76.0% in 2024, and 78.4% in 2025. Total liabilities at the end of 2025 stood at KRW 715.7 billion against total equity of KRW 913.1 billion.

The subsidiary Chong Kun Dang Pharmaceutical attributed its Q3 2026 net income decline partly to higher interest expense. Rising financing costs could increase earnings volatility at the holding level.

Gap between net income and operating profit

In 2024 operating profit rose 108.7%, but net income attributable to controlling shareholders fell 28.5% to KRW 33.6 billion. In 2025 the gap between net income of KRW 54.3 billion and net income attributable to controlling shareholders of KRW 40.4 billion remained wide.

The recurring gap suggests operating gains do not fully reach shareholders, which is a bearish factor. Non-operating items and non-controlling interest effects need continued monitoring.

10

Risk factors

Government drug pricing regulation

The business report says Chong Kun Dang Pharmaceutical's revenue is affected by government regulation, including price re-evaluations, the revision of the list of reimbursed drugs, the tiered drug pricing system, and the co-bioequivalence 1+3 system.

Changes to these systems can affect both pharmaceutical revenue and margins at the subsidiary. Because the holding company consolidates subsidiary results, regulatory shifts can flow directly into earnings. The direction of regulation is an external variable the holding company cannot control.

Exchange rates and financing costs

Chong Kun Dang Pharmaceutical attributed the Q3 2026 net income decline to foreign currency translation losses from exchange rate moves and higher interest expense. With the debt-to-equity ratio higher than in 2022, financing costs remain an item to monitor.

Net income can fall even when operating profit rises if non-operating results worsen. This structure increases the volatility of net income attributable to controlling shareholders.

New drug development and approval timelines

CKD Bio has applied for Chinese marketing approval of a botulinum toxin product, and the timing of entry into China depends on the review outcome. The microbiome drug pipeline and the API subsidiary's preparation for ADC CDMO entry also depend on clinical and regulatory steps.

If approvals are delayed or clinical results fall short, the timeline for medium-term profitability improvement could slip. The timing of realizing these growth drivers remains uncertain.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 business report. Q4 2026 results and full-year operating profit will first be confirmed in a periodic report, and whether the decline in operating profit since Q3 continued into Q4 is the key point to check.

  2. Mid-May 2027

    Filing of the Q1 2027 quarterly report. Whether the operating margin recovers from the Q3 2026 level and whether net income attributable to controlling shareholders returns to profit are the points to check.

  3. Timing of review result not yet fixed

    The result of the Chinese marketing approval review for CKD Bio's botulinum toxin product. The approval outcome will determine the timing of China market entry and the subsidiary's product portfolio.

12

Overall view

Chongkundang Holdings is a pure holding company that consolidates subsidiary results, and the clearest trend in its reported figures is the recovery from an operating loss of KRW 32.9 billion in 2022 to operating profit of KRW 58.3 billion in 2025.

Operating profit grew in both 2024 and 2025, and the operating margin rose to 6.1%.

However, operating profit peaked in Q1 2026 at KRW 19.3 billion and then declined for two consecutive quarters, and Q3 2026 recorded operating profit of KRW 3.57 billion and a net loss attributable to controlling shareholders of KRW 1.99 billion.

The debt-to-equity ratio was 78.4% in 2025, higher than in 2022, and in 2024 net income attributable to controlling shareholders fell even though operating profit rose.

The subsidiary Chong Kun Dang Pharmaceutical's preliminary Q3 2026 results and its improved cumulative operating cash flow are positive signals at the subsidiary level, but they should be read separately from the holding company's consolidated figures.

Government drug pricing regulation and exchange rate and financing cost variables act as both strengths and weaknesses. The next items to confirm are the Q4 and full-year operating profit in the 2026 business report and whether the operating margin recovers in Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. hedgenaru.com
  2. kind.krx.co.kr
  3. kind.krx.co.kr
  4. kind.krx.co.kr
  5. etoday.co.kr
  6. psythinktank.com
  7. comp.fnguide.com
  8. kr.investing.com
  9. dailypharm.com
  10. vegannews.co.kr
  11. m.news.nate.com
  12. alphabiz.co.kr
  13. news.bizwatch.co.kr
  14. asiatoday.co.kr
  15. kpanews.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis